Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...
Plus: FEMA pauses some North Carolina aid efforts over threats{beacon} 12:30 REPORT It’s a quiet Monday morning. Today is ...